AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00394381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion of autologous CIK cells
Description: Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients
Study NCT02520518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ad libitum dietary intake
Study NCT02520518 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ad libitum dietary intake
Study NCT02520518 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary restriction
Study NCT03054077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad with downloaded games
Description: iPad with downloaded games will be given to children randomized to group 2 for use during their time in the peri-operative unit
Study NCT02221596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: 50,000IU/wk of vitamin D3
Study NCT02221596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: 50,000IU/wk of vitamin D3
Study NCT02221596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic training
Description: 7 days of treadmill training during the 13th week of study
Study NCT02221596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: 7 days of treadmill training during the 13th week of study
Study NCT05261789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Turkish Get Up exercise
Description: Before the exercise, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes. 7 different steps (1. Starting position, 2. Supine kettlebell lift, 3. Elbow-supported kettlebell lift, 4. Hand-supported kettlebell lift, 5. High bridge, 6. Half-kneeling and lunge position, 7. Standing up) and the return of these different steps, a total of 2 stages exercise program was applied.~The exercise was started with 3 repetitions for each side and 3 sets with a 30-second rest period between repetitions, and 2 minutes of rest between sets. At the beginning of the 3rd week, the exercise was applied as 3 sets of 4 repetitions, and at the beginning of the 5th week, 3 sets of 5 repetitions were applied. At the end of the exercise, cool-down exercises (low intensity jogging and static stretching) were applied for 5 minutes.
Study NCT05261789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability exercise
Description: After the individuals were taught how to activate their core muscles before the exercise, they were asked to do bridge, prone and lateral bridge exercises by contracting their core muscles. Before the exercises, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes.~Bridge exercise, prone bridge exercise, lateral bridge exercise were applied
Study NCT05261789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
Study NCT02563769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clavulanic acid
Description: Clavulanic acid will be administered orally in 250mg capsules
Study NCT02563769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine
Description: 20/40mg Cocaine will be administered by IV
Study NCT00788112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Study NCT04709744 — intervention group
Intervention type: DRUG
Intervention: Vitamin D
Description: Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes
Study NCT04709744 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Measure vitamin D level
Study NCT03659201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neosil complete
Description: Oral, during 24 weeks.
Study NCT03659201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantogar
Description: Oral, placebo for 12 weeks and pantogar for 12 weeks.
Study NCT03659201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neosil
Description: Oral, during only 12 weeks.
Study NCT00719823 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Maraviroc
Description: Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
Study NCT00605904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
Study NCT00605904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine
Description: Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
Study NCT00605904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yohimbine
Description: Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
Study NCT00605904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mCPP
Description: Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
Study NCT00605904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mCPP
Description: Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
Study NCT00605904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)
Study NCT00605904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)
Study NCT02247063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Definition Transcranial Direct Current Stimulation (HD-tDCS)
Description: HD-tDCS is a non-invasive brain neuromodulatory method for M1 that involves sending a weak electrical current into your brain.
Study NCT02247063 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-Definition Transcranial Direct Current Stimulation (HD-tDCS)
Description: HD-tDCS is a non-invasive brain neuromodulatory method for M1 that involves sending a weak electrical current into your brain.
Study NCT03165149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group (A)
Description: patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.
Study NCT03165149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group (B)
Description: patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
Study NCT03165149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group (c)
Description: patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
Study NCT00961636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER niacin (+) laropiprant (ERN/LRPT)
Description: One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
Study NCT00961636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER niacin (+) laropiprant (ERN/LRPT)
Description: One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
Study NCT00788112 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study NCT00788112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00788112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01842308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation
Description: Undergo autologous stem cell transplant
Study NCT01842308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous stem cell transplant
Study NCT01842308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT01842308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01842308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT04657952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion Block
Description: Sphenopalatine Ganglion Block will be performed by a transnasal approach. Few drops of lidocaine 2% will be instilled into both anterior nares. Then a cotton-tipped applicator soaked in 4% lignocaine \& adrenaline (1 to 200000 will be passed through both the nares and the end of the applicator tip will be positioned just superior to the middle turbinate and anterior to the pterygopalatine fossa and sphenopalatine ganglion for 5 min with the patient in the supine position.
Study NCT04657952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Treatment
Description: Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day. If adequate pain relief will not be achieved, intravenous diclofenac 75 mg twice daily will be added.
Study NCT00578864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protracted Oral Etoposide
Description: Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4~Day 1 - 5~* Hour 0: Etoposide 50 mg/m2 po daily~* Hours 1 to 7: Cisplatin 40 mg/m2~Day 6 - 14~* Etoposide 50 mg/m2 po once daily
Study NCT00578864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~* Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if \< 12 kg) with Mesna 400 mg/m2 (13 mg/kg if \< 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~* Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if \< 12 kg) IV over 15 minutes
Study NCT00578864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~* Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if \< 12 kg) with Mesna 400 mg/m2 (13 mg/kg if \< 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~* Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if \< 12 kg) IV over 15 minutes
Study NCT00578864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Bolus Etoposide
Description: Cisplatin with Bolus IV Etoposide~Day 1~Hours 0 to 6: Cisplatin 40 mg/m2~Days 2, 3, 4:~Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2~Day 5:~Hours 0 to 6: Cisplatin 40 mg/m2
Study NCT00578864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cycle 1, 2, and 4
Study NCT00578864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cycle 1, 2, and 4
Study NCT00578864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cycle 3 and 5 with doxorubicin
Study NCT00578864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cycle 3 and 5 with doxorubicin
Study NCT00578864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: Standard weight-based dosing with cyclophosphamide
Study NCT00961636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Description: Two 1g tablets ERN (2g total) once daily for 12 weeks.
Study NCT00961636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ERN/LRPT
Description: One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
Study NCT03658499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: two day skills group plus treatment adjuncts
Description: The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will be provided with the treatment adjuncts.
Study NCT03658499 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: two day skills group control group
Description: The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will not be provided with the treatment adjuncts and will serve as the control group
Study NCT00578864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Standard weight-based dosing with cyclophosphamide
Study NCT00578864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hematopoietic Factor
Description: Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4
Study NCT00578864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hematopoietic Factor
Description: Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4
Study NCT00578864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary tumor resection
Description: Resection of primary tumor after cycle 3, 4, or 5 as clinically appropriate
Study NCT00578864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary tumor resection
Description: Resection of primary tumor after cycle 3, 4, or 5 as clinically appropriate
Study NCT02531789 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: C3, C4, CRP, and the dilution marker total IgG, together with C3dg, TCC and Bb will be measured over a high-sampling frequency time course t=-1 (admission), 0 (induction), 2,4,8,16, 24, 36 and 48 hours.
Study NCT02280291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ankle SSB
Description: general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
Study NCT02280291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ankle OnQ
Description: versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
Study NCT00788112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00788112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT03687281 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The questionnaire consists of three parts:~* knowledge assessment;~* socio-demographic, medical and lifestyle data;~* use of Chemsex.
Study NCT03220438 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation
Study NCT03220438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation
Study NCT00799565 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: catch of blood
Description: 4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.~This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects
Study NCT02212860 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Then Surgery
Description: Stereotactic image-guided neoadjuvant ablative radiation (randomized to single dose of 21 Gy or three 10 Gy doses) followed by lumpectomy for early stage breast carcinoma
Study NCT01021800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MIS
Description: Cell infusion
Study NCT02746809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreValve Evolut 34R TAVR system
Description: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:~1. Evolut 34R Transcatheter Aortic Valve (TAV)~2. EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~3. EnVeo R Loading System (LS)
Study NCT01471184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops
Study NCT01471184 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Eye Drops/Nasal Spray
Study NCT01352884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-224
Description: Escalating doses of AMP-224
Study NCT01352884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-224
Description: Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood
Study NCT00529048 — intervention group
Intervention type: OTHER
Intervention: Oral Glucose Tolerance Test
Description: The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.
Study NCT02280291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR SSB
Description: general anesthesia/sedationwith a single shot; general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
Study NCT02280291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR OnQ
Description: versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
Study NCT03796091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Brochure
Description: Participants will read an educational brochure from the National Eating Disorders Association and will receive treatment referral resources.
Study NCT03796091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Project Traditional
Description: Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Traditional group therapy program (see Stice \& Shaw, 2001).
Study NCT03796091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Project Expanded
Description: Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Expanded group therapy program (see Green et al., 2017).
Study NCT02514928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy
Description: Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
Study NCT02514928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard pancreatoduodenectomy
Description: Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
Study NCT02640846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine will be given to the patient due to septic shock. After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.
Study NCT02640846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.